[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"South Egypt Cancer Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":114},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635679","phase-2-improving-postoperative-analgesia-after-functional-endoscopic-surgery-100635679",false,"NCT07555821","Improving Postoperative Analgesia After Functional Endoscopic Surgery","Improving Postoperative Analgesia After Functional Endoscopic Surgery: Sphenopalatine Ganglion Block Versus Soaked Nasal Packing Using Bupivacaine and Dexmedetomidine","Inclusion Criteria:\n\n1. Age 18 - 60 years\n2. ASA physical status I -II\n3. Patients scheduled for elective FESS\n\nExclusion Criteria:\n\n1. Allergy to drugs used\n2. Coagulopathy or anticoagulant therapy\n3. Severe cardiovascular, renal and hepatic disease\n4. Chronic opioid use Pregnancy","ALL","18 Years","60 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine",[28],"Pain Management After Functional Endoscopic Sinuscopy","NOT_YET_RECRUITING","2026-04-21",{"date":32,"type":33},"2026-04-29","ACTUAL",{"date":35,"type":21},"2026-04-15",{"date":37,"type":21},"2026-10-30",{"name":39,"class":40},"South Egypt Cancer Institute","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100628063","effect-of-low-dose-pregabalin-retard-825-mg-versus-standard-dose-pregabalin-retard-165-mg-on-postoperative-pain-and-opioid-consumption-after-elective-laparoscopic-abdominal-surgery-100628063","NCT07456761","Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery","Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial","Inclusion Criteria:\n\n* Age 18-75 years\n* ASA physical status I-III\n* Scheduled for elective laparoscopic abdominal surgery under general anesthesia (e.g. laparoscopic cholecystectomy, appendectomy, diagnostic\u002Ftherapeutic laparoscopic procedures without expected conversion to open surgery)\n* Ability to understand the NRS pain scale and the study procedures\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Known allergy or intolerance to pregabalin, gabapentinoids, or study medications\n* Chronic opioid use (daily use \\>30 mg oral morphine equivalent for \\>2 weeks preoperatively)\n* Regular use of gabapentin or pregabalin within 30 days\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or on dialysis\n* Severe hepatic impairment (Child-Pugh C)\n* Uncontrolled epilepsy or other major neurological disorder\n* Severe psychiatric disease, alcohol or substance abuse\n* Pregnancy or breastfeeding\n* Planned postoperative ICU admission for reasons other than routine overnight monitoring\n* Conversion to open abdominal surgery (these patients will be analyzed in sensitivity or excluded, predefined in analysis plan)","75 Years",{"count":51,"type":21},80,[53],"NA","The goal of this clinical trial is to detect whether pregabalin retard (82.5 mg or 165 mg) improves analgesia after elective laparoscopic abdominal surgery in adults. It will also evaluate the safety of both doses.\n\nThe main questions it aims to answer are:\n\nDoes the higher dose (165 mg) reduce the total amount of opioids needed in the first 24 hours after surgery compared to the lower dose (82.5 mg)? Do the pain scores differ between the two doses? Are there differences in side effects between the two doses?\n\nResearchers will compare two different doses of pregabalin retard to determine which provides better pain control with fewer side effects.\n\nParticipants will:\n\nTake one dose of pregabalin retard (82.5 mg or 165 mg) before surgery Receive standard anesthesia and multimodal pain treatment Have their pain levels and opioid use monitored for 24 hours after surgery Be assessed for side effects such as dizziness, nausea, or sedation",[56],"Laparoscopic Abdominal Surgeries",[58,59,60,61],"Pregabalin","Pain scores","Total opioid consumption","Laparoscopic abdominal surgery","2026-04-01",{"date":64,"type":33},"2026-04-02",{"date":66,"type":21},"2026-04",{"date":68,"type":21},"2026-12",{"name":39,"class":40},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":79,"maxAge":49,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100626330","adding-magnesium-sulfate-to-combined-pecto-intercostal--serratus-anterior-planes-block-on-post-operative-analgesia-in-patients-undergoing-modified-radical-mastectomy-100626330","NCT07434232","Adding Magnesium Sulfate to Combined Pecto-Intercostal & Serratus Anterior Planes Block on Post-operative Analgesia in Patients Undergoing Modified Radical Mastectomy","Efficacy of Adding Magnesium Sulfate to Combined Pecto-Intercostal & Serratus Anterior Planes Block on Post-operative Analgesia in Patients Undergoing Modified Radical Mastectomy: A Prospective, Randomized Controlled Clinical Trial","Mastectomy","Inclusion Criteria:\n\n* Female patients aged 30 to 75 years diagnosed with non-metastatic breast cancer and scheduled for modified radical mastectomy.\n* ASA, I-III and NYHA, I-II.\n* Written informed consent.\n\nExclusion Criteria:\n\n* ASA physical status \\>III and NYHA \\>II,\n* body mass index \\>40 kg\u002Fm2,\n* pregnant women,\n* Patients with organ failure or coagulation disorders.\n* Allergy to local anesthetics or magnesium sulfate\n* Contraindications as local infection\n* History of chronic pain or opioid use .\n* Unwilling to participate in the study","FEMALE","30 Years",{"count":81,"type":21},100,[53],"Here, in our study, we intend to compare the analgesic efficacy of magnesium sulfate as an adjuvant to local anesthetics added to the Pecto-Intercostal Fascial Block (PIFB) vs the Serratus Anterior Plane Block (SAPB) in patients undergoing modified radical mastectomy.\n\nStudy Endpoints Primary Endpoints: Total intravenous opioid consumption during the first 24 hours following surgery. Secondary Endpoints: Postoperative analgesia, 24 hours after surgery, assessed using the Visual Analog Scale (VAS) and time to first analgesic request.",[85],"Modified Radical Mastectomy","2026-02-22",{"date":88,"type":33},"2026-02-25",{"date":90,"type":21},"2026-02-15",{"date":92,"type":21},"2027-04-15",{"name":39,"class":40},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":78,"minAge":17,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100626648","adding-magnesium-sulphate-to-combined-pectointercostal-plane-and-erector-spinae-plane-blocks-for-acute-and-chronic-post-mastectomy-pain-100626648","NCT07438366","Adding Magnesium Sulphate to Combined Pectointercostal Plane and Erector Spinae Plane Blocks for Acute and Chronic Post-Mastectomy Pain","Efficacy of Adding Magnesium Sulphate to Combined Pectointercostal Plane Block and Erector Spinae Plane Block for Acute and Chronic Post-Mastectomy Pain After Modified Radical Mastectomy. A Controlled Clinical Trial","Inclusion Criteria:\n\n* Female patients aged ≥18 years.\n* American Society of Anesthesiologists (ASA) class I-III.\n* Scheduled for unilateral modified radical mastectomy.\n\nExclusion Criteria:\n\n* Known allergy to local anesthetics or magnesium.\n* Coagulopathy or anticoagulant therapy.\n* Local infection at injection site.\n* Body mass index (BMI) ≥ 40 kg\u002Fm2.\n* Chronic opioid use or chronic pain disorders.\n* Neurological or psychiatric disorders affect pain perception.\n* Severe hepatic or renal impairment.\n* Pregnancy.\n* Lactation.","65 Years",{"count":103,"type":21},60,[53],"Given the burden of chronic postmastectomy pain and the need for effective, opioid-sparing analgesia, the propose of the randomized controlled trial is to evaluate the safety and efficacy of adding magnesium sulphate to the combination of PIP block and ESPB in patients undergoing modified radical mastectomy for reducing acute and chronic post mastectomy pain",[107],"Post-mastectomy Pain Syndrome",{"date":109,"type":33},"2026-02-27",{"date":90,"type":21},{"date":112,"type":21},"2027-02-15",{"name":39,"class":40},""]